Jazz Pharmaceuticals plc

JAZZ ·Healthcare, Drug Manufacturers - General
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2009
Revenue $128.4M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $36.6M
SG&A Expense $58.7M
Operating Income $15.9M
Operating Margin 12.4%
Interest Expense $22.8M
Pretax Income
Income Tax Expense
Net Income $-6.8M
Net Margin -5.3%
EPS (Basic) $-0.23
EPS (Diluted) $-0.23
Shares Outstanding (Basic) 30.0M
Shares Outstanding (Diluted) 30.0M
Dividends Per Share
← Newer Page 3 of 3 Older →